Collegium Pharmaceutical, Inc. (COLL) Stock Analysis & Investment Frameworks
Collegium Pharmaceutical, Inc. (COLL) stock analysis on Invetso. Review Collegium Pharmaceutical, Inc.’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Collegium Pharmaceutical, Inc. Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: US
Collegium Pharmaceutical, Inc. Key Financial Metrics
- Market Cap: $788.17M
- Revenue: $780.57M
- P/E Ratio: 12.54
- ROE: 12.49%
- ROIC: 7.03%
- Dividend Yield: N/A
About Collegium Pharmaceutical, Inc.
Collegium Pharmaceutical, Inc. (COLL) is a specialized pharmaceutical firm dedicated to the development and marketing of medications for pain management. Its diverse product lineup features significant therapies aimed at addressing various pain conditions. A prominent offering is Xtampza ER, an extended-release, oral formulation of oxycodone, specifically engineered with properties to deter abuse. This particular drug is prescribed for patients experiencing severe, persistent pain that necessitates daily, continuous, long-term opioid therapy. The company's portfolio also encompasses Nucynta ER and Nucynta IR, which are extended-release and immediate-release versions of tapentadol, respectively. Founded in 2002, the enterprise initially operated under the name Collegium Pharmaceuticals, Inc., before officially adopting its current identity as Collegium Pharmaceutical, Inc. in October 2003. The company's corporate headquarters are situated in Stoughton, Massachusetts.